Difference between revisions of "Sorafenib (Nexavar)"
m (→Also known as) |
m |
||
| Line 10: | Line 10: | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| + | *[[Non-small cell lung cancer]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
*[[Thyroid cancer]] | *[[Thyroid cancer]] | ||
| Line 44: | Line 45: | ||
[[Category:Hepatobiliary cancer medications]] | [[Category:Hepatobiliary cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2005]] | [[Category:Drugs FDA approved in 2005]] | ||
Revision as of 20:29, 27 December 2016
General information
Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Hepatobiliary cancer
- Melanoma
- Non-small cell lung cancer
- Renal cancer
- Thyroid cancer
Patient drug information
- Sorafenib (Nexavar) package insert PDF pages 26-30[1]
- Sorafenib (Nexavar) patient drug information (Chemocare)[4]
- Sorafenib (Nexavar) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/20/2005: FDA approved "for the treatment of patients with advanced renal cell carcinoma (RCC)."
- 11/16/2007: FDA approved "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)."
- 11/22/2013: FDA approved "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment"
Also known as
BAY 43-9006, BAY 54-9085, Sorafenib Tosilate
References
- Drug index
- Chemotherapy
- Oral chemotherapy
- Kinase inhibitors
- BRAF inhibitors
- FLT3 inhibitors
- KIT inhibitors
- PDGFR inhibitors
- RET inhibitors
- VEGF inhibitors
- Acute myeloid leukemia medications
- Hepatobiliary cancer medications
- Melanoma medications
- Non-small cell lung cancer medications
- Renal cancer medications
- Thyroid cancer medications
- Drugs FDA approved in 2005